Update on terbinafine with a focus on dermatophytoses
Jason G Newland1,3, Susan M Abdel-Rahman2,3
Divisions of Infectious Diseases1 and Clinical Pharmacology and Medical Toxicology2, Children’s Mercy Hospitals and Clinics, Kansas City, MO, USA; 3Department of Pediatrics, University of Missouri-Kansas City, School of Medicine, Kansas City, MO, USA
Abstract: Since terbinafine was introduced on the world market 17 years ago, it has become the leading antifungal for the treatment of superficial fungal infections, aided by unique pharmacologic and microbiologic profiles. This article reviews mode of action, antimycotic spectrum and disposition profile of terbinafine. It examines the data, accumulated over 15 years, on the comparative efficacy of terbinafine (vs griseofulvin, itraconazole, fluconazole) in the management of the infections for which it is primarily indicated (eg, dermatophytoses) and provides a brief discussion on its use for the treatment of non-dermatophyte infections. Finally, the available data on the newest topical and systemic formulations are introduced.
Keywords: tinea, Trichophyton, Microsporum, allylamine, antifungal
This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php